- The trend backdrop is active with a 19-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is constructive, supporting the smart-money activity read.
UPR
LSE
Week ended 07 Aug 2026
Weekly Investor Report
Uniphar plc · Healthcare · Medical Distribution
Latest close
365.0 GBP
-1.9%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 0.3% above the Trend Line and sits at 56.4% of its 52-week range. The latest completed week returned -1.9%, after a -6.9% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal.
Setup score
47
out of 100
Latest Close
365.0 GBP
7 Aug 2026
1W Return
-1.9%
latest completed week
4W Return
-6.9%
short-term follow-through
12W Return
-2.7%
quarterly tape
Trend Breadth
67.3%
35 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- Activity pressure is negative, which weakens the current setup.
- 2 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-1.9%
Latest completed week; four-week move -6.9%.
Indicator stack
82/27
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
51/100
13 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 0.3% above the Trend Line and sits at 56.4% of its 52-week range. The latest completed week returned -1.9%, after a -6.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.8412-week average 0.88
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership10/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.84Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -6.9% over four weeks, -2.7% over 12 weeks, and 8.0% over one year. The current trend has remained active for 19 consecutive weeks.
Performance by holding period
Active trend streak19 weeks
Active weeks in one year35
Trend breadth67.3%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.57Latest activity-pressure read.
Pressure change-161.3%Four-week change in activity pressure.
Leadership-3.67Latest relative-leadership reading.
RS change-152.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 91%
Model confidence 72%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength22/100Blend of value, momentum, and quality. Underlying universe rank 79; rank 1 is best.
Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.
Quality11/100Profitability and accounting quality. Underlying universe rank 90; rank 1 is best.
Momentum82/100Medium-term price momentum. Underlying universe rank 19; rank 1 is best.
Growth16/100Revenue and earnings growth. Underlying universe rank 85; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework60/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 19.0x Price divided by trailing earnings.
- Price / sales
- 0.3x Market value relative to trailing revenue.
- EV / EBITDA
- 10.9x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 3.5% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 14.9% Gross profit retained from each unit of revenue.
- Operating margin
- 3.0% Operating profit retained from revenue.
- Free-cash-flow margin
- 1.5% Free cash flow generated from revenue.
- Return on invested capital
- 9.3% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 11.0% Latest one-year revenue growth.
- EPS growth
- -16.3% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 105.7% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.5% Cash dividends relative to market value.
- Buyback yield
- 3.6% Net share repurchases relative to market value.
- Shareholder yield
- 4.1% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.7x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment51/100
Weighted news tone is neutral across 13 relevant articles.
1 positive · 12 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-13.1%Distance below the 52-week high.
13-week volatility2.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+5.7%Week of 10 Apr.
Worst week-4.2%Week of 27 Mar.
Latest week-1.9%Week of 7 Aug.
Shape of recent returns
Strong gains3
Modest gains10
Flat weeks0
Modest losses12
Sharp losses1
Recent vol2.3%13-week weekly-return volatility.
Base vol2.6%52-week weekly-return volatility.
Up/down split24/26Count of positive and negative weeks in the 52-week window.
Average skew2.5% / -1.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorGB Healthcare
4-week rank58 / 79
Group average0.0%
Trend breadth27.8%
Trend27.8%active weekly trend signals
MD44.3%positive activity pressure
RS22.8%positive relative leadership
Four-week leaders
IndustryGB Medical Distribution
4-week rank1 / 1
Group average-6.9%
Trend breadth100.0%
Trend100.0%active weekly trend signals
MD0.0%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape51/100
Trend, activity pressure, participation, and risk combine to a 51/100 tape read.
Indicator analysis78/100Latest 12-week confirmation: trend 12/12, activity pressure 10/12, relative leadership 10/12.
Activity pressure 0.84; 2 reversal markers Factors30/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 17; Small Cap Core rank 47 SVQF60/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 105.0 of 260 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment51/100Weighted news tone is neutral across 13 relevant articles.
Uniphar PLC Revenue Breakdown – LSE:UPR Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 365.0 GBP | -1.9% | 363.8 GBP | 267.4 GBP | -0.57 | -3.67 | 286.7K | On |
| 31 Jul 2026 | 372.0 GBP | -2.9% | 362.0 GBP | 266.7 GBP | -0.14 | -1.72 | 500.8K | On |
| 24 Jul 2026 | 383.0 GBP | -0.8% | 359.6 GBP | 265.9 GBP | 0.30 | 2.19 | 389.4K | On |
| 17 Jul 2026 | 386.0 GBP | -1.5% | 356.8 GBP | 265.1 GBP | 0.62 | 4.31 | 90.2K | On |
| 10 Jul 2026 | 392.0 GBP | -1.5% | 354.1 GBP | 264.6 GBP | 0.94 | 7.04 | 60.2K | On |
| 3 Jul 2026 | 398.0 GBP | 1.3% | 351.5 GBP | 263.8 GBP | 1.12 | 6.89 | 31.3K | On |
| 26 Jun 2026 | 393.0 GBP | -2.2% | 349.0 GBP | 262.8 GBP | 1.16 | 7.35 | 3.0K | On |
| 19 Jun 2026 | 402.0 GBP | -3.4% | 346.7 GBP | 262.1 GBP | 1.28 | 11.39 | 187.2K | On |
| 12 Jun 2026 | 416.0 GBP | 0.5% | 344.1 GBP | 261.2 GBP | 1.33 | 14.08 | 54.4K | On |
| 5 Jun 2026 | 414.0 GBP | 4.0% | 341.5 GBP | 260.4 GBP | 1.24 | 14.88 | 15.0K | On |
| 29 May 2026 | 398.0 GBP | 2.6% | 338.9 GBP | 259.5 GBP | 1.08 | 10.38 | 782.7K | On |
| 22 May 2026 | 388.0 GBP | 3.5% | 337.0 GBP | 258.7 GBP | 0.88 | 7.26 | 1.1M | On |
| 15 May 2026 | 375.0 GBP | 1.4% | 335.5 GBP | 258.0 GBP | 0.63 | 6.66 | 1.1M | On |
| 8 May 2026 | 370.0 GBP | 4.8% | 334.1 GBP | 257.5 GBP | 0.65 | 5.08 | 121.7K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.